Value Investing Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: J Mako who wrote (44934)	10/12/2011 9:55:32 AM
From: Spekulatius	1 Recommendation Read Replies (2) of 78659

>>what characteristics of the CRO business make it a lousy business?<< Business has no growth outlook, many phama companies are looking to shrink their research budget CRO has no moat and no IP CRO always carry the risk of cancellation if a drug does not work, this causes lumpy results for CRO's Customers are fairly concentrated and way larger than CRO organizations The whole idea to employ CRO's for pharma's is to keep the essential IP part of the discovery process in house and move the expensive clinical trial part to a lower cost organization.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next